773 related articles for article (PubMed ID: 9024260)
1. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
2. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
[TBL] [Abstract][Full Text] [Related]
3. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
[TBL] [Abstract][Full Text] [Related]
4. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
Van den Berghe G; de Zegher F; Baxter RC; Veldhuis JD; Wouters P; Schetz M; Verwaest C; Van der Vorst E; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Feb; 83(2):309-19. PubMed ID: 9467533
[TBL] [Abstract][Full Text] [Related]
6. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
Shah N; Evans WS; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
[TBL] [Abstract][Full Text] [Related]
7. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
[TBL] [Abstract][Full Text] [Related]
8. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
[TBL] [Abstract][Full Text] [Related]
9. Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.
Veldhuis JD; Evans WS; Bowers CY
J Clin Endocrinol Metab; 2002 Feb; 87(2):859-66. PubMed ID: 11836333
[TBL] [Abstract][Full Text] [Related]
10. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
[TBL] [Abstract][Full Text] [Related]
11. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
[TBL] [Abstract][Full Text] [Related]
12. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.
Shah N; Evans WS; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2000 Aug; 85(8):2649-59. PubMed ID: 10946861
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
Van den Berghe G; Wouters P; Bowers CY; de Zegher F; Bouillon R; Veldhuis JD
Eur J Endocrinol; 1999 Jan; 140(1):17-22. PubMed ID: 10037246
[TBL] [Abstract][Full Text] [Related]
14. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Iranmanesh A; Veldhuis JD; Bouillon R
Clin Endocrinol (Oxf); 2002 May; 56(5):655-69. PubMed ID: 12030918
[TBL] [Abstract][Full Text] [Related]
15. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
Iranmanesh A; South S; Liem AY; Clemmons D; Thorner MO; Weltman A; Veldhuis JD
Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.
Van den Berghe G; Wouters P; Weekers F; Mohan S; Baxter RC; Veldhuis JD; Bowers CY; Bouillon R
J Clin Endocrinol Metab; 1999 Apr; 84(4):1311-23. PubMed ID: 10199772
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone secretagogues in critical illness.
Van den Berghe G
Horm Res; 1999; 51 Suppl 3():21-8. PubMed ID: 10592440
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
Bowers CY; Granda-Ayala R
Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
[TBL] [Abstract][Full Text] [Related]
19. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
[TBL] [Abstract][Full Text] [Related]
20. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]